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Objective: Patients with peripheral artery disease (PAD) have varying degrees of walking disability that do not completely
correlate with ankle-brachial index (ABI) or angiographic anatomy. We hypothesized that endothelial function (EF) is an
independent predictor of symptom severity in PAD patients.
Methods: This was a cross-sectional study of 100 PAD patients presenting to a vascular surgery clinic. All patients received
ABI testing and brachial artery ﬂow-mediated, endothelium-dependent vasodilation (FMD) to assess arterial EF.
Symptom severity and walking disability reported by Rutherford category was based on the patient’s self-report during
the clinic visit and recorded by the investigator-vascular surgeons. Demographic, biochemical, and physiologic parameters
were entered into regression equations to determine association with symptom severity.
Results: Patients were a mean age of 66 6 8 years, and 43% had diabetes. Mean FMD was 7.4%, indicating impaired EF.
EF progressively declined as Rutherford category increased (P[ .01). Brachial artery FMD, ABI, systolic blood pressure,
C-reactive protein, low-density lipoprotein, high-density lipoprotein, b-blocker use, and a history of diabetes or coronary
artery disease were all associated with Rutherford category (all P < .05). Multivariable regression showed EF (P < .02) and
ABI (P < .0001) were independently associated with walking disability. When the cohort was restricted to claudicant
patients (n [ 73), EF remained associated with walking disability after adjustment for other covariates (P [ .0001).
Conclusions: Symptom severity in PAD is multifactorial, reﬂecting impaired hemodynamics and vascular dysfunction. This
is the ﬁrst report demonstrating that walking disability in PAD is associated with arterial EF. The mechanistic link
underlying these observations remains to be deﬁned. (J Vasc Surg 2014;59:1025-34.)the Department of Surgery, University of California San Franciscoa;
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://dx.doi.org/10.1016/j.jvs.2013.10.084Close to one-third of primary care patients aged
>70 years develop peripheral artery disease (PAD).1 It
has recently been reported that PAD is a worldwide
disease, and its incidence has increased by nearly a quarter
in the last decade.2 An advanced stage of the disease is
characterized by impaired ambulation, loss of functional
capacity, pain, nonhealing wounds, and limb loss that
confer signiﬁcant morbidity and mortality. The advanced
age and disability of patients with PAD also make them
a highly vulnerable population for major cardiovascular
events3; furthermore, loss of ability to exercise can further
contribute to a decline in cardiovascular ﬁtness. Under-
standing factors involved in walking impairment is there-
fore critical and could point toward strategies aiming to
target the speciﬁc pathophysiologic mechanisms involved.
Mechanisms of walking impairment in PAD remain
poorly understood but are likely multifactorial and involve
impaired hemodynamics, abnormal muscle characteristics,
arterial stiffness, and inﬂammation.4-17 Previous studies
have demonstrated that the ankle-brachial index (ABI) and
other measures of PAD often poorly correlate with symp-
toms.18,19 The mechanisms responsible for walking impair-
ment may involve factors beyond reduced blood ﬂow, such
as arterial stiffness, inﬂammation, arteriogenesis, nerve
impairment and muscle dysfunction. It is presently un-
clear whether endothelial dysfunction is related to walking
impairment in PAD and the relationships between ABI,
endothelial function (EF), and PAD-related functional1025
Table I. Rutherford category used in the study
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relationships in a prospective cohort of patients with PAD.Grade Category Clinical Distance
0 0 Asymptomatic
I 1 Mild claudication >3 blocks
I 2 Moderate claudication >1 and #3 blocks
I 3 Severe claudication #1 block
II 4 Ischemic rest pain
III 5 Minor tissue loss
III 6 Major tissue lossMETHODS
The investigator-initiated protocol of this study was
approved by the University of California, San Francisco
Committee on Human Research. All patients gave
informed consent.
Study population and protocol
This cross-sectional study investigated the relationship
between EF and walking disability in PAD patients.
Patients referred to the outpatient vascular surgery clinic
of San Francisco Veterans Affairs Medical Center
(SFVAMC) for evaluation of PAD were recruited. Patients
with PAD were enrolled if they had at least one of the
following inclusion criteria: symptoms of PAD (claudica-
tion or critical limb ischemia [CLI]) associated with an
ABI of <0.9, toe pressures of <70 mm Hg, or imaging
conﬁrming >50% stenosis in the lower extremity arteries.
Patients without PAD, coronary artery disease (CAD),
cerebrovascular disease (CVD), and an ABI >0.9 were
enrolled as controls. Exclusion criteria included signiﬁcant
renal, hepatic, or inﬂammatory disease, concurrent severe
infections, acute illness or other major surgery #30 days,
or taking immunosuppressive medications. We recorded
demographic and anthropometric data, cardiovascular
history, risk factors, concurrent medications, and pertinent
cardiovascular examination ﬁndings. EF was measured by
ﬂow-mediated brachial artery vasodilation (FMD). Other
measurements included high-sensitivity C-reactive protein
(hsCRP), lipid panel (low-density lipoprotein [LDL],
triglycerides, high-density lipoprotein [HDL], total choles-
terol), blood pressure, and bilateral ABIs.20
Measurements
Demographic and anthropometric data, hemody-
namic measurements and walking distance. Demo-
graphic and anthropometric data collected included age,
race, sex, hip and waist circumference, body mass index,
prior supplement use, and exercise frequency. We collected
cardiovascular history, such as CAD, CVD, and previous
procedures, as well as risk factors including hypertension,
diabetes, hypercholesterolemia, cigarette smoking, and
renal insufﬁciency. Concurrent medications and pertinent
cardiovascular examination ﬁndings were also recorded.
Blood pressure was measured by an indirect sphygmoma-
nometer. Walking distance and Rutherford classiﬁcation
was based on the patient’s self-report during the clinic
visit and recorded by the investigator-vascular surgeons
(Table I).
Vascular reactivity of brachial arteries. FMD
measurement was performed according to current guide-
lines and standards.21,22 Subjects were asked to fast
($8 hours) and abstain from nicotine ($4 hours) before
the examination. The examination took an average of
40 minutes and was performed by the research assistantunder the direct supervision of a vascular surgeon. A
history of recent medications was recorded.
Participants were allowed to rest for 10 minutes in
a supine position in a darkened room at 23C. The
subject’s arm was extended onto a movement-
constraining pillow with the palmar aspect oriented anteri-
orly. A 5-cm tourniquet blood pressure cuff was placed on
the upper arm proximal to the insertion of the deltoid. The
length of the brachial artery was surveyed by B-mode ultra-
sound imaging (HD11; Philips Medical Systems, Bothell,
Wash) using a broadband linear array transducer with
a 3- to 12-MHz range (L12-3; Philips Medical Systems)
until a straight segment with a visible registration structure
could be located. The probe was oriented so that the artery
was at least 3 cm deep to the surface of the skin, the focus
aligned with the deep boundary of the vessel, and clearly
demarcated intima/lumen boundaries were visible.
Before cuff inﬂation, the baseline diameter of the vessel
was recorded for 60 seconds using electrocardiogram-
gated image capture software (Brachial Imager; Medical
Imaging Applications LLC, Coralville, Iowa). Baseline
blood-ﬂow velocity was recorded for 60 seconds using an
insonation angle of 60. The Doppler sample gate was
positioned to cover the center, but not the edges, of the
lumen. The probe was not moved between measurements.
The blood pressure cuff was inﬂated to the greater of
250 mm Hg or 50 mm Hg above the subject’s systolic
blood pressure for 5 minutes. Recording of the B-mode
images began 10 seconds before cuff release. Blood-ﬂow
velocity was assessed for 30 seconds after cuff release using
the methods described above. B-mode images were
recorded until 3 minutes after cuff release.
Analyses of the images were performed using contin-
uous edge-detection software (Brachial Analyzer; Medical
Imaging Applications LLC). Baseline diameter was
recorded as the mean of 60 seconds of data. From hyper-
emia recordings, the exact moment of cuff release was
noted. Hyperemia diameter was calculated using a predeter-
mined time window (55-65 seconds after cuff release). The
FMD percentage was calculated as (60-second hyperemia
diameter e average baseline diameter/average baseline
diameter)  100.
Time averaged velocity measurements were obtained
using the peak-velocity method. Average velocity at base-
line was obtained from 60 seconds of data. Velocity of
the hyperemia stimulus was calculated as the mean velocity
JOURNAL OF VASCULAR SURGERY
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and the velocity time integral were recorded.
Quality control was assessed at each point of the
measurements. Image quality was evaluated by a second
person and graded on a 6-point scale that included registra-
tion structure (landmark), horizontally directed artery,
correct longitudinal alignment, clearly visualized near-wall
and far-wall intimal medial thickness, and at least 5 mm
of clearly visualized artery. The interobserver variability in
our laboratory is 0.05% 6 0.16%, and the intraobserver
variability is 0% 6 0.15%.
ABI. ABIs were measured using current guidelines
and standards.20 The procedure takes an average of
10 minutes. Systolic blood pressures of the brachial,
posterior tibial, and dorsalis pedis arteries were measured
bilaterally. For each lower extremity, the highest systolic
pressure of the two pedal pulses was divided by the highest
systolic pressure of the two brachial arteries.
Renal, lipid, metabolic, and inﬂammatory mea-
surements. Blood samples were collected in a fasting state
for measurement of creatinine, estimated glomerular ﬁltra-
tion rate, albumin, hemoglobin A1c if diabetic, and total
cholesterol, triglycerides, LDL, and HDL. Plasma was
assayed for these analytes the same day as collection by
the SFVAMC laboratory per standard methodology on
a Beckman Coulter Analyzer (Beckman Coulter, Miami,
Fla). Serum was isolated at the same time points for homo-
cysteine and assayed the same day as collection by the
SFVAMC laboratory per standard methodology on an
Architect i1000 Analyzer (Abbott Diagnostics, Lake
Forest, Ill). The inﬂammatory marker hsCRP was
measured from plasma assayed the same day according to
standard methodology (Beckman Coulter Analyzer). The
coefﬁcient of variation for hsCRP using this procedure is
5.1%.
Statistical analysis
For descriptive purposes, we categorized participants
a priori by Rutherford category. They were then further
grouped by PAD category for the overall analysis (no
PAD, Rutherford 0; claudicant patients, Rutherford 1 to
3; and CLI, Rutherford 4 to 6). Differences in baseline
characteristics were compared with the use of analysis of
variance for continuous variables and the c2 test for dichot-
omous variables. Because hsCRP had a skewed distribu-
tion, it was log-transformed for statistical analyses. For
the overall regression models, patients were divided by
PAD category (no PAD, Rutherford 0; claudicant patients,
Rutherford 1 to 3; and CLI, Rutherford 4 to 6). For
regression models in claudicant patients, the Rutherford
category was used as a categoric variable. We used multi-
variable linear regression models to determine the relation-
ship, expressed as adjusted means by category, between the
PAD category or Rutherford category and FMD. Multivar-
iate adjustment was made for demographic characteristics
as well as covariates known to inﬂuence the Rutherford
category based on an a priori determination of signiﬁcance
at P < .05 on univariate models. Models were thenrepeated to assess the relationship between the ABI and
symptomatology of patients. Statistical analyses were per-
formed using Stata/SE 12 (StataCorp, College Station,
Tex).
RESULTS
A total of 100 patients participated in this study,
including 73 with claudication, 19 with CLI, and eight
without PAD. Table II demonstrates the demographics,
comorbidities, medications, and PAD risk factors associated
with all participants as well as with each of these groups.
Patients were a mean age of 66 6 8 years, 91% had hyper-
tension, 87% had diagnosed hyperlipidemia, 39% had
a history of CAD, and 43% had diabetes mellitus. Increasing
Rutherford category was associated with a lower FMD,
lower ABI, higher systolic blood pressure, and a higher inci-
dence of diabetes mellitus and CAD as well as higher CRP
and lower albumin (Table II and Figs 1 and 2).
In assessing factors predicting the Rutherford category
symptomatology of patients using a univariate analysis, the
factors with strongest association included FMD (P <
.0001), ABI (P < .0001), b-blocker use (P < .0001),
LDL (P ¼ .001), HDL (P ¼ .006), CRP (P ¼ .007),
a history of CAD (P ¼ .002) or diabetes mellitus (P ¼
.006), and systolic blood pressure (P ¼ .01). After adjust-
ment for these factors, FMD was still signiﬁcantly associ-
ated with Rutherford category (Table III), with an
adjusted mean FMD of 11.4% in controls, 8.0% in claudi-
cant patients, and 5.3% in CLI patients (P ¼ .02). Within
the same cohort, the ABI also remained signiﬁcantly asso-
ciated with Rutherford category after adjustment for
factors associated with walking impairment (Table III),
whereas none of the other factors remained associated
with Rutherford category.
When the cohort was restricted to the 73 claudicant
patients, brachial artery FMD decreased with worsening
Rutherford category (Table IV). A strong association was
also found between FMD and walking impairment (P ¼
.00011; Table V). After adjustment for age, race, systolic
blood pressure, index ABI, LDL, HDL, CRP, diabetes
mellitus, history of CAD, and b-blocker use, FMD
remained signiﬁcantly associated with walking impairment,
with an adjusted mean FMD of 11.4% in patients with
Rutherford category 1, 9.3% with Rutherford category 2,
and 6.6% with Rutherford category 3 symptoms (P ¼
.0008; Table V). The ABI did not hold a signiﬁcant inde-
pendent association with walking impairment in claudicant
patients nor did the other factors (Table V).
FMD and index ABI were not correlated in the entire
cohort (P ¼ .18), indicating that FMD independently
predicts symptom severity.
DISCUSSION
In a cross-sectional cohort study of patients presenting
to our outpatient vascular surgery clinic, we found a signif-
icant association between EF, as measured by brachial
artery FMD, and disease severity in patients with PAD.
Because the ABI and FMD were not correlated, we
Table II. The baseline characteristics of the population categorized by peripheral arterial disease (PAD) category
Characteristicsa
All patients
No PAD Claudication CLI
P(N ¼ 100) Rutherford 0 (n ¼ 8) Rutherford 1-3 (n ¼ 73) Rutherford 4-6 (n ¼ 19)
Age, years 66 6 8 63 6 8 67 6 8 67 6 9 .47
Male sex 100 (100) 8 (100) 73 (100) 19 (100) .
Caucasian 67 (67) 3 (38) 53 (73) 11 (58) .09
BMI, kg/m2 28 6 5 29 6 3 28 6 5 26 6 6 .47
Waist-to-hip ratio, % 1.0 6 0.1 0.98 6 0.07 1.01 6 0.06 1.0 6 0.3 .11
Blood pressure, mm Hg
Systolic 139 6 22 132 6 22 136 6 18 152 6 29 .008
Diastolic 75 6 10 77 6 8 75 6 9 76 6 13 .74
Index ABI 0.68 6 0.2 1.04 6 0.24 0.69 6 0.15 0.50 6 0.15 <.0001
Brachial FMD, % 7 6 4 11 6 3 7 6 4 6 6 5 .01
Comorbidities
Hypertension 91 (91) 6 (75) 67 (92) 18 (95) .24
Hyperlipidemia 87 (87) 6 (75) 66 (90) 15 (79) .24
History of CAD 39 (39) 1 (13) 26 (36) 12 (63) .03
Diabetes mellitus 43 (43) 0 (0) 31 (42) 12 (63) .01
Medications
Aspirin 66 (66) 3 (38) 47 (64) 16 (84) .06
ACE inhibitor 42 (42) 1 (13) 34 (47) 7 (37) .16
b-Blocker 61 (61) 2 (25) 44 (60) 15 (79) .03
Statin 85 (85) 5 (63) 65 (89) 15 (79) .10
Insulin 22 (22) 0 (0) 13 (18) 9 (47) .006
PAD risk factors
History of smoking 94 (94) 7 (88) 69 (95) 18 (95) .72
Cholesterol, mg/dL
Total 153 6 42 186 6 41 154 6 42 134 6 37 .01
LDL 83 6 38 116 6 43 82 6 36 70 6 33 .01
HDL 41 6 13 44 6 5 43 6 13 36 6 13 .09
Triglycerides, mg/dL 151 6 92 129 6 53 154 6 97 149 6 87 .77
Serum creatinine, mg/dL 1.1 6 0.3 1.0 6 0.2 1.1 6 0.3 1.1 6 0.4 .63
Homocysteine, mmol/L 13.3 6 4.8 10.1 6 2.5 13.7 6 4.9 13.2 6 4.8 .13
CRP, mg/L 10.2 6 25.7 4.1 6 2.7 6.8 6 19.8 25.2 6 41.1 .02
eGFR, mL/min/1.73 m2 79 6 25 83 6 19 78 6 23 80 6 31 .87
Albumin, g/dL 3.9 6 0.4 4.1 6 0.1 3.9 6 0.4 3.6 6 0.4 .004
ABI, Ankle-brachial index; ACE, angiotensin-converting enzyme; BMI, body mass index; CAD, coronary artery disease; CLI, critical limb ischemia; CRP, C-
reactive protein; eGFR, estimated glomerular ﬁltration rate; FMD, ﬂow-mediated dilation; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
aCategoric data are shown as number (%) and continuous data as mean 6 standard deviation.
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walking disability independently of ABI. However, the
mechanisms underlying this association remain to be
elucidated.
Multifactorial etiology of walking disability in
patients with PAD. Walking disability in patients with
PAD is likely multifactorial and involves abnormal muscle
characteristics, inﬂammation, impaired hemodynamics,
and arterial dysfunction. In addition to the inadequacy of
arterial blood ﬂow and collateralization, many tissue anal-
yses and animal studies have shown that overall adverse
calf muscle characteristics6 can be attributed to impaired
calf muscle mitochondrial function,5 impaired calf muscle
function and metabolism,5-7 reduced tissue perfusion, and
lean muscle atrophy.4 Increased calf muscle proteolysis,
coupled with inﬂammation,8-10 also plays a key role in
walking disability. CRP is known to lead to release of
endothelial monocyte chemoattractant protein-1, which
attracts monocytes to the endothelium, upregulation of
tissue factor and proinﬂammatory cytokines, such as tumor
necrosis factor-a, inhibition of nitric oxide, and inductionof endothelial adhesion molecules, such as soluble intercel-
lular adhesion molecule 1 and soluble vascular cell adhesion
molecule 1, leading to adhesion of monocytes to the
endothelium.19-21McDermott et al14-16 previously dem-
onstrated that inﬂammatory markers including CRP, IL-6,
soluble intercellular adhesion molecule-1, and soluble
vascular cell adhesionmolecule-1 are associated with shorter
walking distance and slower walking speeds.19-21
To our knowledge, this report is the ﬁrst to examine the
relationship between walking disability and EF evaluated by
brachial artery FMD in a PAD cohort. Several studies have
found that endothelial dysfunction and reduced
endothelium-mediated vasoreactivity are associated with
PAD severity.23,24 Coutinho et al13 explored the philos-
ophy behind the potential inﬂuence of EF in the functional
decline of PAD patients. Various clinical trials followed and
showed that greater physical activity and exercise could
enhance EF as measured by FMD.25-27 We therefore
conﬁrm through this cross-sectional study that EF assessed
by brachial artery FMD can serve as a risk marker for
symptom severity and impaired physical activity in patients
Fig 1. Relationship between symptomatic status of patients and
brachial ﬂow-mediated dilation (FMD). Brachial artery FMD is
shown by peripheral arterial disease (PAD) category in the entire
cohort, unadjusted data. P value indicates difference between
groups using analysis of variance. The horizontal line in the middle
of each box indicates the median; the top and bottom borders of the
box mark the 75th and 25th percentiles, respectively, the top and
bottom whiskers mark the 90th and 10th percentiles, respectively;
and the black circle indicates outliers.
Fig 2. Relationship between symptomatic status of claudicant
patients and brachial ﬂow-mediated dilation (FMD) is shown by
Rutherford category in patients with claudication, unadjusted data.
The P value indicates the difference between groups using analysis
of variance. The horizontal line in the middle of each box indicates
the median; the top and bottom borders of the box mark the 75th
and 25th percentiles, respectively, the top and bottom whiskersmark
the 90th and 10th percentiles, respectively; and the black circle
indicates outliers.
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 4 Grenon et al 1029with PAD. There is still controversial evidence over the
effect of the nitric oxide-mediated vasodilation mechanism
and whether nitric oxide supplementation can improve
claudication distance and exercise tolerance in PAD
patients.28,29 Thus, further studies are warranted to delve
into the physiologic relationship between EF and walking
disability as well as therapeutic strategies.
Arterial function, the ABI, and EF. Arterial function
can be described by arterial stiffness and EF. Arterial stiff-
ness, measured by pulse-wave analysis and velocity and
augmentation index, has been associated with greater
functional impairment.11 Impaired hemodynamics and
degree of arterial stenosis, as measured by ABI, should
intuitively inﬂuence walking disability as well. The ABI is
a simple and quick method of detecting PAD that is ofﬁce-
based, noninvasive, inexpensive, and easily reproducible.20
Nevertheless, a meta-analysis reviewing 33 clinical studies
with 1237 PAD patients showed that clinical improvements
were not entirely correlated with ABI.30
Although numerous epidemiologic studies have
demonstrated that the ABI is an independent predictor
of mortality,31-34 its relationship to claudication symptoms
is not entirely clear. Furthermore, its relationship to EF is
not fully understood. For example, a study of PAD
patients found a low ABI was independently related to
a low FMD.35 In another study assessing PAD severity
and inﬂammation, FMD was found to correlate with
ABI.36 Still, other studies have found no correlations
between the ABI and FMD.37 In our patient population,
EF and ABI were both associated with walking impair-
ment, although they were not directly correlated. This
suggests that EF and ABI are both factors that couldindependently inﬂuence symptomatology of patients
with PAD.
Although our ﬁndings indicate that decreasing ABI was
independently associated with patient-reported claudication
symptoms, the measurement of ABI at rest may not be the
best reﬂection of PAD severity. Patients found to have
a normal ABI (>0.9) may still have signiﬁcant leg pain at
rest due to mild disease or arterial occlusive symptoms,
which can produce a false-negative ABI reading. Exercise
testing before and after ABI assessment, rather than resting
ABI, has been shown to be a more sensitive screening tool
for these patients.38-40 Exercise, which can include a graded
treadmill testing, a 6-minute walk test, active pedal plantar
ﬂexion,40 or even an arm-leg ergometry,41 affects ﬂow
across a moderately stenotic vessel and exposes a lower
ABI compared with rest. If the exercise ABI readings are
within normal reference ranges, then leg pain is likely not
associated with PAD and can suggest a neurogenic cause
or muscle pathology. If the postexercise ABI measurements
are in the abnormal range, then PAD is more likely.
b-blockade and claudication symptom severity.
Patients with PAD have, by deﬁnition, systemic atheroscle-
rosis and are highly likely to be affected by CAD as well. A
number of lifestyle factors are known to contribute to the
progression of atherosclerosis and development of CAD
and PAD, the most signiﬁcant being hypertension,
smoking, dyslipidemia, poor glycemic control, and
increased levels of circulating inﬂammatory biomarkers.
b-Blockade medications, which are among the most
common medical therapy prescribed to patients with
PAD, serve mainly to mitigate the detrimental effects of
uncontrolled hypertension. To this point, 61% of patients
Table IV. Characteristics of claudication patients by Rutherford classiﬁcation
Characteristicsa Rutherford 1 (n ¼ 9) Rutherford 2 (n ¼ 12) Rutherford 3 (n ¼ 52) P
Age, years 63 6 5 69 6 10 67 6 8 .24
Male sex 9 (100) 12 (100) 52 (100) .
Caucasian 5 (56) 10 (83) 38 (73) .37
BMI, kg/m2 30 6 6 27 6 5 28 6 5 .41
Waist-to-hip ratio, % 0.99 6 0.04 1.01 6 0.05 1.02 6 0.07 .38
Blood pressure, mm Hg
Systolic 129 6 13 141 6 24 136 6 18 .31
Diastolic 80 6 11 77 6 9 73 6 9 .076
Index ABI 0.74 6 0.11 0.73 6 0.17 0.67 6 0.15 .21
Brachial FMD, % 12 6 3 9 6 3 6 6 4 .0001
Comorbidities
Hypertension 7 (78) 12 (100) 48 (92) .18
Hyperlipidemia 9 (100) 11 (92) 46 (88) .55
History of CAD 1 (11) 4 (33) 21 (40) .24
Diabetes mellitus 5 (56) 4 (33) 22 (42) .59
Medications
Aspirin 6 (67) 9 (75) 32 (62) .67
ACE inhibitor 2 (22) 5 (42) 27 (52) .24
b-Blocker 2 (22) 5 (42) 37 (71) .008
Statin 8 (89) 12 (100) 45 (87) .40
Insulin 1 (11) 3 (25) 9 (17) .70
PAD risk factors
History of smoking 8 (89) 12 (100) 49 (94) .53
Cholesterol, mg/dL
Total 165 6 51 166 6 47 150 6 39 .34
LDL 95 6 45 89 6 39 78 6 34 .34
HDL 46 6 12 49 6 17 40 6 12 .08
Triglycerides, mg/dL 120 6 77 140 6 74 163 6 105 .42
Serum creatinine, mg/dL 0.97 6 0.17 0.96 6 0.28 1.09 6 0.33 .04
Homocysteine, mmol/L 11.7 6 3.3 13.3 6 3.9 14.3 6 5.4 .35
CRP, mg/L 4.5 6 3.1 4.6 6 5.5 7.8 6 23.6 .82
eGFR, mL/min/1.73 m2 77 6 12 87 6 25 76 6 24 .38
ABI, Ankle-brachial index; ACE, angiotensin-converting enzyme; BMI, body mass index; CAD, coronary artery disease; CRP, C-reactive protein; eGFR,
estimated glomerular ﬁltration rate; FMD, ﬂow-mediated dilation; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PAD, peripheral arterial
disease.
aCategoric data are shown as number (%) and continuous data as mean 6 standard deviation.
Table III. Adjusted means of brachial artery ﬂow-mediated dilation (FMD) and adjusted ankle-brachial index (ABI) by
peripheral arterial disease (PAD) category in the entire cohort
Model
Controls (Rutherford 0) Claudication (Rutherford 1-3) CLI (Rutherford 4-6)
PAdjusted mean, % 95% CI Adjusted mean, % 95% CI Adjusted mean, % 95% CI
Brachial artery FMD
Model 1 11.0 8.3-13.7 7.4 6.5-8.3 5.8 4.0-7.7 .01
Model 2 10.6 7.8-13.4 7.4 6.5-8.4 5.8 4.0-7.6 .02
Model 3 11.4 8.2-14.6 8.0 7.0-8.9 5.3 3.2-7.5 .02
ABI
Model 4 1.04 0.93-1.15 0.69 0.65-0.72 0.50 0.42-0.57 <.0001
Model 5 1.05 0.93-1.16 0.68 0.65-0.72 0.50 0.43-0.58 <.0001
Model 6 0.99 0.87-1.11 0.69 0.67-0,74 0.58 0.49-0.67 <.0001
CAD, Coronary artery disease; CI, conﬁdence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Model 1, base model; Model 2, base
model, age and race; Model 3, base model, age, race, systolic blood pressure, ABI, LDL, HDL, C-reactive protein, diabetes mellitus, history of CAD and
b-blocker; Model 4, base model; Model 5, base model, age, and race; Model 6, base model, age, race, systolic blood pressure, brachial FMD, LDL, HDL,
C-reactive protein, diabetes mellitus, history of CAD, and b-blocker.
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high proportion to mean that use of this medication is
a strong surrogate for atherosclerotic disease burden.
Atherosclerotic plaque deposition is associated with
stiffer and more stenotic vessels, weakened EF, and re-duced vasoreactivity. Our ﬁndings indicate that such
impairments in vascular function have important clinical
signiﬁcance, namely in reducing walking capacity. Despite
optimal medical therapy aimed at known risk factors (along
with b-blockers, this includes additional antihypertensive
Table V. Adjusted means of brachial artery ﬂow-mediated dilation (FMD) and adjusted ankle-brachial index (ABI) by
Rutherford classiﬁcation in the claudicant patients
Model
Rutherford 1 Rutherford 2 Rutherford 3
PAdjusted mean, % 95% CI Adjusted mean, % 95% CI Adjusted mean, % 95% CI
Brachial artery FMD
Model 1 11.7 9.5-13.9 8.9 7.0-10.8 6.3 5.3-7.2 .0001
Model 2 11.6 9.4-13.8 8.8 6.9-10.7 6.3 5.4-7.2 .0001
Model 3 11.4 9.2-13.6 9.3 7.4-11.1 6.6 5.6-7.5 .0008
ABI
Model 4 0.74 0.65-0.84 0.73 0.64-0.84 0.67 0.63-0.71 .21
Model 5 0.75 0.64-0.85 0.73 0.65-0.82 0.67 0.62-0.71 .18
Model 6 0.73 0.62-0.85 0.73 0.64-0.82 0.68 0.63-0.73 .57
CAD, Coronary artery disease; CI, conﬁdence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Model 1, base model; Model 2, base
model, age and race; Model 3, base model, age, race, systolic blood pressure, ABI, LDL, HDL, C-reactive protein, diabetes mellitus, history of CAD, and
b-blocker; Model 4, base model; Model 5, base model, age and race; Model 6, base model, age, race, systolic blood pressure, brachial FMD, LDL, HDL,
C-reactive protein, diabetes mellitus, history of CAD, and b-blocker.
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do not experience clinical improvement. In fact, frequency
of b-blocker use in our cohort increased with worsening
symptomatology: 22%, 42%, and 71% of patients across
grades I, II and III, respectively. This raises the important
concern that current available medications, although help-
ful at reducing cardiovascular risk, are not enough and that
there is a need to identify additional therapies that augment
the endothelial dysfunction associated with PAD.
Interventions to improve EF. One such promising
therapy is ramipril, an angiotensin-converting enzyme
inhibitor that was recently shown to improve exercise
capacity and enhance quality of life in patients with symp-
tomatic PAD. A 24-week trial, documented an average 77%
improvement in pain-free walking and a 123% gain in
maximal walking time, corresponding to 75-second and
255-second increases, respectively.42 The authors proposed
that angiotensin-converting enzyme inhibition with ramipril
may induce vasodilation by way of reduction in angiotensin
II and also improve peripheral blood ﬂow and EF due to
bradykinin preservation, thus leading to better functioning.
These ﬁndings are especially exciting when comparing with
cilostazol and pentoxifylline, the only medications currently
approved by the United States Food and Drug Adminis-
tration for treatment of claudication associated with PAD,
with cilostazol conferring a greater symptomatic beneﬁt that
approaches 25%.43
Another emerging intervention that may lead to
improvement in EF is supplementation with n-3 polyunsat-
urated fatty acids (PUFAs). In one notable study of young,
healthy smokers, Siasos et al44 found that FMD values
signiﬁcantly improved after oral treatment with 2 g/d of
n-3 PUFAs at various time intervals spanning several
months. The reasoning underlying this correlation is that
fatty acids may improve EF by decreasing the elevated
oxidative stress caused by smoking. Supplementation with
n-3 PUFAs could lead to recovery of endothelial synthesis
of nitric oxide and prostaglandin I2, as well as vascular
smooth muscle cell sensitivity to nitric oxide. Thesemechanisms are especially relevant to the cohort evaluated
in our study, 94% (n ¼ 94) of whom were current or past
smokers and had proinﬂammatory proﬁles as a result.
Exercise can also be prescribed as an effective therapy
for patients with claudication. Beneﬁcial effects of exercise
may include increasing collateral ﬂow, improving EF
through increased nitric oxide-dependent vasodilation
and thereby improving ABI, augmenting mitochondrial
energy production, and decreasing circulating inﬂamma-
tory molecules.45 Exercise therapy therefore has the poten-
tial to reverse the pathologic mechanisms associated with
PAD and interrupt progression toward further disability.
One study testing a 6-month exercise rehabilitation inter-
vention in symptomatic PAD patients and controls found
signiﬁcant improvements in treadmill times to onset and
maximal claudication pain, as well as ABI.46 A randomized
study of 156 PAD patients by McDermott et al47 found
that 6 months of treadmill exercise led to an increase in
FMD, implying improvement in EF and symptom
improvement: exercising patients’ 6-minute walk distance
increased by 20.9 m compared with a decline of 15 m in
nonexercising controls. Postexercise ABI was not reported,
although in theory, improvement could be expected in the
setting of improved hemodynamics.
Another randomized controlled trial of 104 patients
with PAD and intermittent claudication showed that per-
forming arm or leg exercises, compared with no therapy
among controls, improved time to onset of claudication
and maximal walking distance at 6, 12, 18, and 24 weeks.
Progressive improvements at each time interval were also
observed.48 These results emphasize one of the primary
goals in managing patients with PADdto improve
disease-related impairment.
Limitations. The patient population studied was not
representative of the wider PAD population because it
included only male veterans from SFVAMC referred to
a vascular surgery clinic; hence, the ﬁndings do not extend to
women. It is important to state that this report does not
addressmost patients withPAD, thosewho are asymptomatic.
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self-report by patients and not veriﬁed by a walking
impairment questionnaire, which is another limitation.
Furthermore, there was no direct functional testing using
a treadmill or 6-minute walk test. To address this limita-
tion, the walking impairment questionnaire and 6-minute
walk test have been added to upcoming studies at our
institution.
Another limitation of this study is that the controls
were controls for PAD although they may have had occult
CAD or CVD. Furthermore, this report does not imply
causation but rather an association.
Lastly, although it is known that cigarette smoking
chronically49 and acutely50 alters EF, it is less likely that
cigarette smoking was a factor in the present study because
there was no difference in the baseline FMD of smokers vs
nonsmokers. This is likely related to the very severe athero-
sclerotic burden and disease severity of our patient popula-
tion (ie, veterans with PAD).
CONCLUSIONS
In a contemporary cohort of patients, vascular function,
as measured with brachial artery FMD, is associated with
symptom severity in patients with PAD, independently of
the ABI. This supports the premise that symptom severity
in PAD is multifactorial, adding vascular dysfunction to
other important factors including muscle characteristics,
inﬂammation, and impaired hemodynamics. Although the
mechanisms remain unclear, our data suggest the possibility
that interventions that improve EF could have a positive
effect on symptomatology in patients with PAD.
We acknowledge the comments of Dr Michael S Conte
in the drafting of this manuscript and thank the staff of the
Clinical Research Center of the San Francisco Veterans
Affairs Medical Center for their invaluable help with this
work.
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Submitted Sep 11, 2013; accepted Oct 17, 2013.DISCUSSIONDr Larry Kraiss (Salt Lake City, Utah). Congratulations to
Ms Chong who very ably presented this paper. I also thank the
authors for a timely submission of their paper for my review.
The UCSF group is to be commended for reminding us that
PAD is in reality a systemic disease. They report that self-reported
walking impairment correlates best with objectively measured end-
othelial function, which is a systemic condition as opposed to the
ABI, which might be considered a limb-speciﬁc condition. Walking
impairment is an endpoint that is sensitive to many factors, only one
of which is the ABI or the degree of hemodynamic impairment that
the limb experiences. Also, I think we have all had patients who
underwent intervention for claudication with an improvement in
ABI but a disappointing response in walking distance. So, this partic-
ular conclusion, on its face, is not too difﬁcult to accept, but I do
have some reservations about the data supporting this conclusion.First, although the study population is extensively phenotyped
in terms of endothelial function, ABI, and multiple biochemical
parameters, the clinical characterization is suboptimal. As we
have heard before during this meeting, the venerable Rutherford
classiﬁcation has probably outlived its usefulness, so I question
the accuracy of self-reported walking distance in terms of “blocks.”
There is no information about whether these self-reported
outcomes are accurate or reproducible. Your study would be greatly
strengthened by an objective measure of walking impairment, such
as the 6-minute walk test. While the authors acknowledge this limi-
tation, it remains a major drawback to the study’s impact.
Ms Karen Chong.We acknowledge this as a limitation of our
study. We are therefore excited to launch our trial that will have
a 6-minute walk test as an outcome in addition to self-reported
Rutherford and the WIQ.
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1034 Grenon et al April 2014Dr Kraiss. Second, the authors report that endothelial func-
tion as measured by brachial artery FMD is the only parameter
that correlates with severity of claudication classiﬁed by Rutherford
category. However, in the manuscript, there is a 100% overlap
between endothelial function scores for group II compared to
group III. This challenges my statistical “smell” test.
Finally, the authors report that endothelial function did not
correlate with ABI but the P value for this relationship is .21. So,
there is an 80% chance that ABI and endothelial function really do
correlate. Since there are so few subjects in the Rutherford class I
and II categories, I wonder if it is really true that ABI and endothelial
function do not correlate or whether this is in essence a type II error.
These are issues that I will let the authors address in the JVS
editorial process, as I am not sure that a discussion around these
points will be all that informative this morning. I do have four
straightforward questions for the authors:
1. How were patients selected for the study? Were they consec-
utive? Were they new or established patients, or both?
2. Did inﬂow or outﬂow location of disease correlate with endo-
thelial function?
3. Had any patients in the study received previous treatment
directed at claudication?
4. Have any of the study patients subsequently received treat-
ment for claudication? If so, did endothelial function predict
treatment outcome?This is a worthwhile area of study and I encourage the authors
to continue their investigations. I suspect that they are on to some-
thing that may ultimately help us better select claudicants who will
beneﬁt the most from intervention.
Ms Chong. To answer your questions:
1. We essentially attempted to recruit any patient that came
through our clinic with PAD, provided that they ﬁt our eligi-
bility criteria and provided consent. This included both new
and established patients.
2. We have not yet looked at the location of the disease, but that
is actually the next direction for us. We plan to look at angio-
graphic or MR imaging to determine location of lesions and
quantity of collaterals to see if these factors might correlate
with endothelial function or walking disability.
3. There were patients that had prior revascularization, but this
was the minority. In those cases, we based our clinical Ruther-
ford category on their symptoms prior to any revascularization
to ensure that their native symptoms would be captured.
4. Study patients certainly have subsequently received treatment
for claudication. However, we have not collected these data,
but we do have access to it. It would be interesting to see if
endothelial function does predict treatment outcome. For
now, our lab, the Vascular Integrated Physiology and Experi-
mental Therapeutics Lab (VIPERx), is focusing on establish-
ing a modiﬁable risk factor in patients with claudication.
